Risk of leukemia after platinum-based chemotherapy for ovarian cancer

New England Journal of Medicine

Volumn 340, Issue 5, 1999, Pages 351-357

  Travis, Lois B ^a   Holowaty, Eric J ^b   Bergfeldt, Kjell ^c   Lynch, Charles F ^d   Kohler, Betsy A ^e   Wiklund, Tom ^f   Curtis, Rochelle E ^a   Hall, Per ^c   Andersson, Michael ^g   Pukkala, Eero ^h   Sturgeon, Jeremy ⁱ   Stovall, Marilyn ^j  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CANCER CARE ONTARIO   (Canada)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF IOWA   (United States)

^e Dept of Health and Senior Services ^*  (United States)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^h FINNISH CANCER REGISTRY   (Finland)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARBOQUONE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; IFOSFAMIDE; MELPHALAN; MITOMYCIN; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; PROCARBAZINE; TREOSULFAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LEUKEMOGENESIS; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARBOPLATIN; CASE-CONTROL STUDIES; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA; LOGISTIC MODELS; MELPHALAN; MIDDLE AGED; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 0033521949     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199902043400504     Document Type: Article

References (31)

1. Greene MH. Is cisplatin a human carcinogen? J Natl Cancer Inst 1992; 84:306-12.
2. Donehower RC, Abeloff MD, Perry MC. Chemotherapy. In: Abeloff MD, Armitage JO, Lichter AS, Neiderhuber IE, eds. Clinical oncology. New York: Churchill Livingstone, 1995:201-18.
3. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:2113-9.
4. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29. [Erratum, CA Cancer J Clin 1998;48:192.]
5. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1994. Bethesda, Md.: National Cancer Institute, 1997. (NIH publication no. 97-2789.)
6. Travis LB, Curtis RE, Boice JD Jr, Platz CE, Hankey BF, Fraumeni JF Jr. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996;56:1564-70.
7. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Vol. 7. Lyon, France: International Agency for Research on Cancer, 1997. (LARC scientific publications no. 143.)
8. Stovall M, Smith SA, Rosenstein M. Tissue doses from radiotherapy of cancer of the uterine cervix. Med Phys 1989;16:726-33.
9. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
10. Lubin JH. A computer program for the analysis of matched case-control studies. Comput Biomed Res 1981;14:138-43.
11. Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994;86:1450-7.
12. Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990;322:1-6.
13. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326:1745-51.
14. Kaldor J. Second cancer following chemotherapy and radiotherapy: an epidemiological perspective. Acta Oncol 1990;29:647-55.
15. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986; 105:360-7
16. Ozols RF, Behrens BC, Ostchega Y, Young RC. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 1985;12:Suppl A:59-65.
17. Williams CJ, Stewart L, Parmar M, Guthrie D. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma: the Advanced Ovarian Cancer Trialists Group. Semin Oncol 1992;19:Suppl 2: 120-8.
18. Allen DG, Baak J, Belpomme D, et al. Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 1993;4:Suppl 4:83-8.
19. Smith M, Rubinstein L, Anderson J, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol (in press).
20. Reed E, Parker RJ, Gill I, et al. Platinum-DNA adducts in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 1993;53:3694-9.
21. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment and follow-up, JAMA 1995;273:491-7.
22. Douple EB. Keynote address: platinum radiation interaction. In: Conference on the Interaction of Radiation Theraphy and Chemotherapy. NCI monographs. No. 6. Washington, D.C. Government Printing Office, 1988:315-9. (NIH publication no. 88-2938.)
23. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990;8:911-34. [Erratum, J Clin Oncol 1990;8-1447.]
24. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995;13:1786-99.
25. van Leeuwen FE. Second cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology. 5th ed. Vol. 2. Philadelphia: Lippincott-Raven, 1997:2773-96.
26. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990;322:7-13.
27. Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 1992;52:149-53.
28. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.
29. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15:2691-700.
30. van de Vaart PJ, Klaren HM, Hofland I, Begg AC. Oral platinum analogue JM216, a radiosensitizer in oxic murine cells. Int J Radiat Biol 1997; 72:675-83.
31. Neijt JP. New therapy for ovarian cancer. N Engl J Med 1996;334:50-1.